Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

OCTAPHARMA-PRODUTOS FARMACÊUTICOS LDA

NIF 502820780
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €2,129,017 59 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €2,129,017 59 contracts
A2 · Late Publication €6,776,021,626 1,432 contracts
Contract published to BASE more than 10 days after the signing date
LOW €6,776,021,626 1,432 contracts
A5 · Threshold Splitting €36,277,938 65 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €36,277,938 65 contracts
A6 · Low Competition €1,971,293 22 contracts
Only one bidder participated in a competitive procedure
MEDIUM €1,971,293 22 contracts
A9 · Abnormal Price Reduction €8,403,983,591 630 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €8,403,983,591 630 contracts
C3 · Missing Mandatory Fields €1,824,687 23 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €1,824,687 23 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

113
€448,697,608
19
€446,604,405
270
€420,912,815
115
€354,404,992
80
€332,899,008
80
€331,901,793
40
€321,994,870
35
€306,267,121
121
€296,979,554
20
€287,998,582
44
€272,189,960
32
€268,207,841
41
€257,667,532
138
€253,249,650
50
€252,168,652
18
€247,777,232
128
€228,905,571
16
€228,477,661
17
€225,364,995
44
€222,042,321
Page 1 of 3 · 57 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 1 · 22 contracts

BEAD20250088 - AQUISIÇÃO DE SUBSTITUTOS DO PLASMA E FRAÇ PROT PLASMA
PT · 11236838 · Ao abrigo de acordo-qu...
A6 · Low Competition
€37,650 2025-02-19
Aquisição do medicamento - Fator VIII de coagulação humana e fator de Von Willbrand
PT · 11167430 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€79,308 2024-11-18
BEAD20240494 - AQUISIÇÃO DE IMUNOGLOBULINAS E SOROS
PT · 11002511 · Ao abrigo de acordo-qu...
A6 · Low Competition
€115,830 2024-10-31
241G001496 - IMUNOGLOBULINA SOL INJ 165 MG/ML AMP 24 ML SC ( CUTAQUIG )
PT · 10989804 · Ajuste Direto Regime G...
A6 · Low Competition
€162,162 2024-10-24
31/27/2025 - Medicamento Albumina Humana 5% (g)
PT · 11969381 · Ao abrigo de acordo-qu...
C3 · Missing Mandatory Fields A6 · Low Competition
€281 2024-10-24
BEAD20240531 - AQUISIÇÃO DE PROTEINAS COAGULANTES - COMPLEXO DE PROTROMBINA
PT · 10979170 · Ao abrigo de acordo-qu...
A6 · Low Competition
€10,040 2024-10-18
Ajuste direto para aquisição de DP17 - IMUNOGLOBULINA HUMANA CONTRA O ANTIGÉNIO D (UI) (doentes em tratamento).
PT · 10973339 · Ajuste Direto Regime G...
A6 · Low Competition
€367 2024-10-15
IMUNOGLOBINA HUMANA NORMAL - 3 MESES
PT · 10815817 · Ao abrigo de acordo-qu...
A6 · Low Competition
€111,196 2024-07-11
IMUNOGLOBULINAS E SOROS
PT · 10756695 · Ao abrigo de acordo-qu...
A6 · Low Competition
€10,193 2024-06-06
BEAD20240144 - AQUISIÇÃO DE SUBSTITUTOS DO PLASMA E FRAÇ PROT PLASMA
PT · 10684975 · Ao abrigo de acordo-qu...
A6 · Low Competition
€48,210 2024-04-22
AD 20/2024 Aquisição de Factor VIII da coagulação humana 1000 UI + Factor de Von Willebrand humano 1000
PT · 10765774 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€164,052 2024-04-04
SIMOCTOCOG ALFA 1000 U.I. E 2000 U.I. PÓ SOL INJ FR IV
PT · 10657065 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€0 2024-03-21
DERIVADOS DO PLASMA HUMANO
PT · 11098836 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€69,824 2024-03-04
AQUISIÇÃO DE PLASMA FRESCO CONGELADO C/TRATAMENTO SOLVENTE DETERGENTE GRUPOS A, AB, O - SACO 200 ML AO ABRIGO DO ACORDO QUADRO 2023/438 DOS SPMS, EPE
PT · 10793049 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€20,891 2024-03-04
241G000268/13559 - FACTOR VIII + FACTOR VON WILLEB
PT · 10563185 · Ajuste Direto Regime G...
A6 · Low Competition
€129,412 2024-02-16
SIMOCTOCOG ALFA 1000 e 2000 U.I. PÓ SOL INJ FR IV
PT · 10595029 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€0 2024-02-06
IMUNOGLOBULINAS E SOROS - IMUNOGLOBULINA HUMANA NORMAL
PT · 10533925 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A6 · Low Competition
€145,945 2024-01-31
Derivados do plasma humano ao abrigo do CPA n.º 2020/009
PT · 10601353 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€27,881 2024-01-22
231000687 - PLASMA CONGELADO VIRUS INACTIVADO TIPO A
PT · 10481878 · Ao abrigo de acordo-qu...
A6 · Low Competition
€5,624 2024-01-18
Aquisição de PLASMA HUMANO (ml) ao abrigo do Acordo Quadro 2023/438 para o ano 2024
PT · 10723640 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€160,700 2024-01-11
050100532024 C/ BASE NO CPA 2023_438
PT · 10948385 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€422,641 2024-01-04
PLASMA HUMANO - AQ 2023/438
PT · 10770036 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€249,085 2024-01-04
Overview
Total Value Won
€8,521,941,631
Contracts Won
2,140
Score 69705 · CRITICAL RISK
NIF
502820780
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • M.E. [P-14e1]
    Gerente
    since 2018-07-11
  • D.M. [P-6beb]
    Gerente
    2017-02-22 → 2018-07-11
  • J.P. [P-cc41]
    Gerente
    until 2017-01-05
  • W.H. [P-bf6c]
    Gerente
    until 2017-03-03
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned